GlassScriptPhysician profile
Camille Hoopes
NPI 1457036535
$2,959.60
in general payments reported to CMS, 2019-2025
31 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $714 · 2024: $905 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,917 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.10 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $322.71 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic, INC. | $282.76 | 2023-2025 | Minimed 780g |
| Lilly USA, LLC | $254.04 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $169.06 | 2023 | Korlym |
| Dexcom, INC. | $168.49 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $160.89 | 2024-2025 | |
| Mannkind Corporation | $150.32 | 2023-2025 | Afrezza |
| Insulet Corporation | $148.29 | 2024-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $132.99 | 2023-2025 | Isturisa, Signifor Lar |
| Bayer Healthcare Pharmaceuticals INC. | $119.73 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $113.65 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $86.75 | 2024-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $79.57 | 2023-2025 | Gvoke Hypopen |
| Amgen INC. | $74.00 | 2023-2025 | Evenity, Prolia |
| Halozyme INC | $73.13 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $72.64 | 2023-2024 | Cequr Simplicity |
| Abbvie INC. | $70.21 | 2023-2024 | |
| Averitas Pharma INC. | $56.90 | 2024 | Qutenza |
| Radius Health, INC. | $54.86 | 2023-2024 | Tymlos |
| Ascendis Pharma Endocrinology INC | $53.65 | 2025 | Yorvipath |
| Almatica Pharma LLC | $44.51 | 2025 | Teriparatide |
| Abbott Laboratories | $43.92 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $39.54 | 2023 | Strensiq |
| Neurocrine Biosciences, INC. | $37.76 | 2025 | |
| Antares Pharma, INC. | $33.45 | 2024 | Xyosted |
| Ibsa Pharma INC. | $24.73 | 2024 | Tirosint, Licart |
| Nevro Corp. | $22.77 | 2024 | Senza |
| Tandem Diabetes Care, INC. | $19.67 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $18.77 | 2025 | Rezdiffra |
| Ascensia Diabetes Care US INC. | $15.51 | 2023 | |
| Novo Nordisk INC | $14.33 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Hoopes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.